ACADIA Pharmaceuticals Announces Appointment of Michael J. Yang as Executive Vice President, Chief Commercial Officer
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: Business Wire
Terrence O. Moore Retires as Chief Commercial Officer SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced Michael J. Yang has joined ACADIA as Executive Vice President and Chief Commercial Officer. Mr. Yang succeeds Terrence O. Moore, who has served as ACADIA’s Chief Commercial Officer since 2013, and is now retiring. This Smart News Release features multimedia. View the full release here:http://www.businesswire.com/news/home/20170330005419/en/ Michael J. Yang, Executive Vice President, Chief Commercial Officer (Photo: Business Wire) “I am delighted to welcome Michael to our team,” said Steve Davis, ACADIA’s President and Chief Executive Officer. “Michael is a seasoned executive with extensive exper
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Acadia Pharmaceuticals Inc. (ACAD) InvestigationAccesswire
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the FirmAccesswire
- Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at JPMorgan Chase & Co. from $29.00 to $25.00. They now have an "overweight" rating on the stock.MarketBeat
ACAD
Earnings
- 2/27/24 - Miss
ACAD
Sec Filings
- 3/27/24 - Form 4
- 3/27/24 - Form 4
- 3/27/24 - Form 4
- ACAD's page on the SEC website